For a while now I have been telling anyone who'll listen that New Zealand is on the cusp of a biotech and medtech boom. As a matter of fact, I am so bullish about New Zealand as a Life Sciences investment destination that I have thought seriously about moving there for a while. This morning I've published an essay in which I share what's great about New Zealand before explaining why investors stand to make a lot of money over the next few years backing New Zealand's bio-entrepreneurs.
This is the country that created Fisher & Paykel Healthcare as well as the A2 Milk Company, and, as Xero has shown us, is pretty good at technology. New Zealand has tended to lag Australia and other leading Life Science powers such as the US, the UK and Germany in terms of capitalising on its inherent Life Science potential, but I argue that that is about to change, because the pool of venture capital is getting bigger. In the meantime there are a number of interesting Life Science companies from New Zealand traded on ASX worth looking at. Both Innate Immunotherapeutics and Living Cell Technologies will read out important Phase II data probably in the next 12-18 months. Meanwhile AFT Pharmaceuticals has big growth plans for the next two years. And Volpara Health Technologies is rapidly growing its user base.
For my analysis of New Zealand and the Life Sciences, click here.